
A novel injectable semaglutide-loaded hydrogel formulation demonstrates extended drug release over one month and good tolerability in preclinical studies, potentially improving patient adherence and treatment outcomes for type 2 diabetes and obesity.


coremsg

An injectable hydrogel provided a sustained release of semaglutide for 1 month in rats, according to preclinical testing of an experimental longer-acting formulation.

Monthly Semaglutide Goal: The End of Daily Pills?

experimental-monthly-semaglutide-hydrogel-shows-promise-for-improved-diabetes-and-obesity-treatment


Experimental Monthly Semaglutide Hydrogel Shows Promise for Improved Diabetes and Obesity Treatment
